FIG Makes a Strategic Investment in Elitepharm Laboratoires
President & CEO Narek Sirakanyan stated, "An important step in our industrial growth supported by our AI powered software to improve formulas of dietary supplements."
Freedom International Group (FIG) has announced a strategic investment in Elitepharm Laboratoires, securing a major shareholder position. FIG specializes in technology, finance, health and wellness, managing over 2.5 billion in assets. Elitepharm is renowned for its expertise in formulating and producing customized dietary supplements.
From conceptualizing innovative products to manufacturing private label food supplements, Elitepharm caters to diverse project needs, ranging from small-scale productions to larger operations.
Leveraging AI for Enhanced Nutrition
Narek Sirakanyan expressed enthusiasm about this investment, noting that FIG is entering the healthcare sector with the backing of two innovative businesses, Project V and CoffeeCell. Sirakanyan believes that the region provides an advantageous environment for producing dietary supplements due to its access to high-quality active ingredients and stringent regulatory standards.
FIG plans to integrate its IT subsidiary, Sessia, to channel AI technologies into product development, aiming for increased efficiency and faster, more reliable feedback from focus groups.
Integrating Expertise for Growth
The partnership with Elitepharm is not only logical but synergistic, as Project V produces a diverse range of products, approximately 40 types, utilizing Elitepharm’s extensive capabilities.
This initiative marks a pivotal evolution for Elitepharm Laboratoires, with ambitions to become a leader in Europe’s dietary supplement market, targeting revenues near 50 million euros by 2029. Currently, the company produces about 25 million capsules each month and aims to double that production capacity.
A Vision for Accelerated Growth
The collaboration is anchored in a shared vision of innovation and industrial prowess. Gérard Strauch, who heads Elitepharm, has strategically positioned the company as a bastion of scientific expertise and market insight. His focus on quality and responsiveness has prepared Elitepharm for the growing demands in the industry.
With FIG’s backing, Elitepharm Laboratoires is set to accelerate both commercial and industrial development through enhanced marketing strategies and public relations expertise.
Strategic Areas of Development
This expansion will concentrate on several key strategic areas:
- Enhancement of Facilities: Elitepharm will invest in strengthening existing production capabilities while also acquiring new sites to meet escalating international demand.
- Value Chain Control: Ensuring the highest quality and traceability of ingredients, Elitepharm plans to invest in organic farms dedicated to providing raw materials.
- Private Label Portfolio Expansion: The company aims to grow its product offerings through collaborations with experts and horizontal acquisitions within the industry.
Sirakanyan summarized the acquisition by FIG, stating, "This is an essential move in our vertical integration strategy, aiming for further acquisitions of farms producing organic active ingredients for Elitepharm."
Ambitious Future Goals
Strauch envisions that FIG's investment will propel Elitepharm into a key player within Europe, emphasizing that the partnership shares a mutual strategic vision: "We believe that innovation and industrialization are pivotal to achieving our goals; the future is bright for us."
This collaboration reassures both FIG and Elitepharm's commitment to cultivating a robust and sustainable industrial model that focuses on health and wellness across Europe.
Frequently Asked Questions
What is the significance of FIG’s investment in Elitepharm?
FIG's investment signifies a strategic move to enhance Elitepharm's capacities and expand its market presence in Europe while integrating AI technologies.
How does FIG plan to utilize AI in product development?
FIG aims to employ its IT company, Sessia, to implement AI technologies that will improve product efficiency and market responsiveness.
What are Elitepharm's production goals after this investment?
Elitepharm intends to double its production capacity, reaching its target of 50 million euros in revenues by 2029.
Who are the key figures in this partnership?
Narek Sirakanyan, President & CEO of FIG, and Gérard Strauch, President & CEO of Elitepharm, are leading this strategic alliance.
What is the focus of the partnership between FIG and Elitepharm?
The partnership focuses on innovation, quality control, and meeting the increasing demand for dietary supplements in the European market.
